^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imfinzi (durvalumab)

    i
    Other names: MEDI4736, MEDI-4736, MEDI 4736
    Company:
    AstraZeneca
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    3d
    DeLLphi-313: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=160, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    3d
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    3d
    Sequential chemo-durvalumab, reduced dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial). (PubMed, JNCI Cancer Spectr)
    The early closure of the study and the reduced sample size make it difficult to draw significant conclusions. However, feasibility and safety seem to be acceptable, early PFS and OS data are promising, especially for patients who completed the full treatment sequence.
    Clinical • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab)
    4d
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations (clinicaltrials.gov)
    P3, N=400, Recruiting, Boehringer Ingelheim
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Hernexeos (zongertinib)
    4d
    Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant (clinicaltrials.gov)
    P2, N=8, Terminated, University of Cincinnati | N=30 --> 8 | Active, not recruiting --> Terminated; The study is closing due to low enrollment and feasibility of the study.
    Enrollment change • Trial termination
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    4d
    Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. (PubMed, NPJ Precis Oncol)
    In this study, we evaluated a novel liquid biopsy platform based on circulating cell-free DNA active chromatin (cfDNAac) profiling to identify baseline biomarkers associated with clinical benefit rate (CBR) in 30 LMS patients treated with durvalumab plus olaparib or cediranib. In this analysis, cfDNAac profiling represents a promising non-invasive strategy to predict clinical benefit from CPI-based therapy in LMS. Prospective validation in independent cohorts is warranted to clarify its clinical utility.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    5d
    Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC (clinicaltrials.gov)
    P2, N=1, Terminated, University of Texas Southwestern Medical Center | N=52 --> 1 | Active, not recruiting --> Terminated; Sponsor decision to halt funding.
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion
    |
    Imfinzi (durvalumab)
    5d
    IOSPHERE: Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis (clinicaltrials.gov)
    P2, N=80, Recruiting, Center Eugene Marquis | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    5d
    Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, Fundación GECP
    Trial initiation date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel
    6d
    Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma. (PubMed, Ann Surg Oncol)
    Neoadjuvant therapy followed by curative-intent resection was associated with improved OS, reflecting selection of systemic therapy-responsive high-risk patients with more favorable tumor biology, achieving outcomes similar to those of low-risk groups. Conversely, 45% failed to proceed to surgery due to progression or clinical deterioration, experiencing OS comparable with palliative care.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel
    6d
    Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | N=70 --> 37 | Trial completion date: Oct 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)